Braveheart Bio(BRVE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BRVE Braveheart Bio

交易中 10-13 14:16:37 EDT

19.32

-1.04

-5.13%

最高20.56	最低19.04	成交量10.84万
今开20.44	昨收20.36	日振幅7.47%
总市值17.39亿	流通市值4.99亿	总股本9,004万
成交额212.70万	换手率0.42%	流通股本2,583万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":19.315,"timestamp":1791915390504,"preClose":20.36,"halted":0,"volume":108392,"delay":0,"changeRate":-0.051326129666011695,"floatShares":25831738,"shares":90039000,"eps":-14.684527,"marketStatus":"交易中","change":-1.045,"latestTime":"10-13 14:16:37 EDT","open":20.44,"high":20.56,"low":19.04,"amount":2126961.257904,"amplitude":0.074656,"askPrice":19.43,"askSize":200,"bidPrice":19.26,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-14.684527,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":20.36,"postHourTrading":{"tag":"盘后","latestPrice":20.25,"preClose":20.36,"latestTime":"16:26 EDT","volume":9450,"amount":192376.66,"timestamp":1791836780624,"change":-0.11,"changeRate":-0.005403,"amplitude":0.005403},"volumeRatio":0.4265},"requestUrl":"/m/hq/s/BRVE","defaultTab":"news","newsList":[{"id":"1171302218","title":"新闻稿：Braveheart Bio 宣布扩大规模首次公开募股完成，并完全行使承销商超额配股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1171302218","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171302218?lang=zh_cn&edition=full","pubTime":"2026-08-08 04:09","pubTimestamp":1786133340,"startTime":"0","endTime":"0","summary":"旧金山，2026年8月7日——Braveheart Bio, Inc.是一家临床阶段的生物制药公司，致力于开发针对肥厚型心肌病及其他严重心血管疾病的下一代疗法。该公司今日宣布，其扩大的首次公开募股已完成。此次发行总计24,437,500股普通股，每股发行价为18.00美元，且承销商已完全行使了购买额外3,187,500股的选择权。所有普通股均由Braveheart Bio提供。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4531","LU0154245673.USD","LU0069063385.USD","LU0289961442.SGD","BK4585","LU0689626769.HKD","IPOS","HCM","CMI","IE000M9KFDE8.USD","MADE","LU0057025933.USD","LU0472753341.HKD","LU0289739343.SGD","LU0154245756.USD","BK4533","LU0203347892.USD","BRVE","BK4588","BK4149","LU0203345920.USD","LU0511384066.AUD","BK4567","LU2463526074.USD","LU0124676726.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138238457","title":"异动解读 | IPO首日表现强劲，Braveheart Bio盘中大涨67.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138238457","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138238457?lang=zh_cn&edition=full","pubTime":"2026-08-07 00:52","pubTimestamp":1786035174,"startTime":"0","endTime":"0","summary":"心血管药物开发商Braveheart Bio今日在纳斯达克首日上市交易，盘中股价大涨67.78%，引发市场广泛关注。Braveheart Bio总部位于加州旧金山，是一家处于临床后期的生物制药公司，专注于开发肥厚型心肌病及其他严重心血管疾病的创新疗法。在2026年生物科技IPO热潮的背景下，Braveheart Bio的成功上市进一步彰显了市场对创新药企的强劲信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656478","title":"美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656478","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657656478?lang=zh_cn&edition=full","pubTime":"2026-08-07 00:00","pubTimestamp":1786032000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，心血管药企Braveheart Bio(BRVE.US)登陆美股市场，截至发稿，该股涨超75%，报31.405美元。IPO价格为18美元。Braveheart Bio成立于2024年，是一家处于临床后期的生物制药公司，专注于开发肥厚型心肌病(HCM)及其他严重心血管疾病的创新疗法。公司的核心候选药物BHB-1893(亦称HRS-1893)是一种口服小分子心肌肌球蛋白抑制剂，通过特异性抑制心肌肌球蛋白ATP酶活性，使心肌收缩性能正常化，减少左心室肥厚并改善舒张期顺应性。该药物于2025年9月从中国江苏恒瑞医药获得全球(除大中华区外)独家许可授权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656475","title":"美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657656475?lang=zh_cn&edition=full","pubTime":"2026-08-07 00:00","pubTimestamp":1786032000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657070685","title":"生物科技IPO热潮持续!心血管药企Braveheart(BRVE.US)募资扩大至3.825亿美元，发行价突破指引上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2657070685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657070685?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:28","pubTimestamp":1786004901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","BK4585","IBBJ","BRVE","FRHC","IPOS","KCE","BK4588","BK4127","AGNG","GDOC","MEDX","SYNB","XBI","REDS","BK4581","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655330649","title":"Braveheart Bio(BRVE.US)IPO定价15-17美元/股，拟募资3亿美元推进心血管药物全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2655330649","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655330649?lang=zh_cn&edition=full","pubTime":"2026-07-31 14:34","pubTimestamp":1785479661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UDN","BRVE","IPOS","UUP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.braveheart.bio","stockEarnings":[{"period":"1week","weight":-0.0464},{"period":"1month","weight":-0.2357},{"period":"3month","weight":0.1311},{"period":"ytd","weight":0.1311}],"compareEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":0.0181},{"period":"3month","weight":0.0349},{"period":"6month","weight":0.1117},{"period":"1year","weight":0.1915},{"period":"ytd","weight":0.141}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Braveheart Bio, Inc.于2024年5月13日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为肥厚型心肌病和其他严重心血管疾病患者开发疗法。其主导候选产品BHB-1893是一种下一代口服小分子心肌肌球蛋白抑制剂，由江苏恒瑞医药有限公司获得全球授权，不包括大中华区，并已在恒瑞主要在中国和澳大利亚进行的临床试验中进行评估。","exchange":"NASDAQ","name":"Braveheart Bio","nameEN":"Braveheart Bio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Braveheart Bio(BRVE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Braveheart Bio(BRVE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Braveheart Bio,BRVE,Braveheart Bio股票,Braveheart Bio股票老虎,Braveheart Bio股票老虎国际,Braveheart Bio行情,Braveheart Bio股票行情,Braveheart Bio股价,Braveheart Bio股市,Braveheart Bio股票价格,Braveheart Bio股票交易,Braveheart Bio股票购买,Braveheart Bio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Braveheart Bio(BRVE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Braveheart Bio(BRVE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}